LGND
LIGAND PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$297.28
+0.59%Oct 15, 2026, 11:00 UTC
LIGAND PHARMACEUTICALS INC announced that it will report its third-quarter 2026 financial results on October 29, 2026.
Source:Sep 22, 2026, 11:00 UTC
Ligand Pharmaceuticals acquired a royalty and milestone interest in Santen's Ryjunea from Sydnexis for $23 million.
Source:Aug 6, 2026, 00:00 UTC
Ligand Pharmaceuticals reported Q2 2026 financial results with total revenues of $63.7 million, net income of $48.5 million, and diluted EPS of $2.22.
Aug 6, 2026, 00:00 UTC
Ligand Pharmaceuticals issued convertible debt with an aggregate principal amount of $700 million.
Source:Jul 14, 2026, 13:00 UTC
Ligand Pharmaceuticals completed its acquisition of XOMA Royalty Corporation.
Jun 22, 2026, 00:00 UTC
Ligand Pharmaceuticals entered into a Consent and Fourth Amendment to its Credit Agreement, consenting to its convertible note offering and updating minimum Consolidated EBITDA covenants.